Teva Stock To Go Ex-dividend Tuesday (TEVA)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- The ex-dividend date for Teva Pharmaceutical Industries (NYSE: TEVA) is Tuesday, February 19, 2013. Owners of shares as of market close today will be eligible for a dividend of 26 cents per share. At a price of $38.90 as of 9:31 a.m. ET, the dividend yield is 2.2%.

The average volume for Teva has been 5.4 million shares per day over the past 30 days. Teva has a market cap of $33.62 billion and is part of the health care sector and drugs industry. Shares are up 3.7% year to date as of the close of trading on Thursday.

Teva Pharmaceutical Industries Limited develops, manufactures, and sells pharmaceutical products worldwide. The company has a P/E ratio of 17.2, below the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Teva as a hold. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and generally higher debt management risk. You can view the full Teva Ratings Report.

See our dividend calendar or top-yielding stocks list.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.

null

More from Markets

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Purdue Pharma Unloads Sales Staff, Transitioning From Painkiller Focus

Purdue Pharma Unloads Sales Staff, Transitioning From Painkiller Focus

Dow Finishes Lower as Nasdaq Posts New Record

Dow Finishes Lower as Nasdaq Posts New Record

Airlines Rebuke Trump Policy of Separating Children

Airlines Rebuke Trump Policy of Separating Children

Deutsche Bank Fined $205 Million Over Currency-Trading Violations

Deutsche Bank Fined $205 Million Over Currency-Trading Violations